



**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED DECEMBER 31, 2022**

**(WITH SUMMARIZED FINANCIAL INFORMATION FOR THE  
YEAR ENDED DECEMBER 31, 2021)**

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## CONTENTS

---

<b>Independent Auditors' Report .....</b>	<b>1-2</b>
---	------------

### **Financial Statements**

Statement of Financial Position .....	3
Statement of Activities.....	4
Statement of Functional Expenses .....	5
Statement of Cash Flows .....	6

<b>Notes to Financial Statements.....</b>	<b>7-17</b>
---	-------------

## INDEPENDENT AUDITORS' REPORT

To the Board of Directors of  
**Food Allergy Research & Education, Inc.**

### *Opinion*

We have audited the financial statements of Food Allergy Research & Education, Inc. (FARE), which comprise the statement of financial position as of December 31, 2022, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of FARE as of December 31, 2022, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

### *Basis for Opinion*

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of FARE and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### *Responsibilities of Management for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about FARE's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

## ***Auditors' Responsibilities for the Audit of the Financial Statements***

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- exercise professional judgment and maintain professional skepticism throughout the audit.
- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of FARE's internal control. Accordingly, no such opinion is expressed.
- evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about FARE's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

### ***Report on Summarized Comparative Information***

We have previously audited FARE's 2021 financial statements, and we expressed an unmodified audit opinion on those audited financial statements in our report dated June 20, 2022. In our opinion, the summarized comparative information presented herein as of and for the year ended December 31, 2021, is consistent, in all material respects, with the audited financial statements from which it has been derived.

*Marcum LLP*

Washington, DC  
September 14, 2023

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## STATEMENT OF FINANCIAL POSITION

DECEMBER 31, 2022

(WITH SUMMARIZED FINANCIAL INFORMATION AS OF DECEMBER 31, 2021)

	<u>2022</u>	<u>2021</u>
<b>Assets</b>		
Cash and cash equivalents	\$ 8,127,178	\$ 9,892,876
Investments	26,622,148	33,560,253
Contributions receivable, net	5,000,572	5,573,112
Other receivables	111,859	107,290
Prepaid expenses and other assets	331,079	220,085
Property and equipment, net	83,115	386,727
Right-of-use assets – operating	<u>181,190</u>	<u>--</u>
<b>Total Assets</b>	<u>\$ 40,457,141</u>	<u>\$ 49,740,343</u>
<b>Liabilities and Net Assets</b>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$ 809,580	\$ 785,563
Accrued salaries, leave and other benefits	281,740	212,531
Grants payable	6,762,408	1,149,550
Refundable advances	50,000	--
Lease liability – operating	270,952	--
Deferred rent and lease incentives	<u>--</u>	<u>185,373</u>
<b>Total Liabilities</b>	<u>8,174,680</u>	<u>2,333,017</u>
<b>Net Assets</b>		
Without donor restrictions	20,911,084	34,756,401
With donor restrictions		
Purpose and time restrictions	<u>11,371,377</u>	<u>12,650,925</u>
<b>Total Net Assets</b>	<u>32,282,461</u>	<u>47,407,326</u>
<b>Total Liabilities and Net Assets</b>	<u>\$ 40,457,141</u>	<u>\$ 49,740,343</u>

*The accompanying notes are an integral part of these financial statements.*

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## STATEMENT OF ACTIVITIES

**FOR THE YEAR ENDED DECEMBER 31, 2022**

**(WITH SUMMARIZED FINANCIAL INFORMATION FOR THE YEAR ENDED DECEMBER 31, 2021)**

	Without Donor Restrictions	With Donor Restrictions	2022 Total	2021 Total
<b>Revenue and Support</b>				
Contributions	\$ 3,706,235	\$ 7,583,333	\$ 11,289,568	\$ 11,789,633
Program service fees	459,981	--	459,981	131,916
Special events, net	4,282	--	4,282	11,113
Other revenue	22,370	--	22,370	8,546
Interest income	29,262	--	29,262	2,818
Net assets released from restrictions:				
Satisfaction of program restrictions	7,004,547	(7,004,547)	--	--
Satisfaction of time restrictions	1,858,334	(1,858,334)	--	--
<b>Total Revenue and Support</b>	<u>13,085,011</u>	<u>(1,279,548)</u>	<u>11,805,463</u>	<u>11,944,026</u>
<b>Expenses</b>				
Program services	21,525,101	--	21,525,101	17,301,881
Supporting services	4,789,328	--	4,789,328	7,079,932
<b>Total Expenses</b>	<u>26,314,429</u>	<u>--</u>	<u>26,314,429</u>	<u>24,381,813</u>
<b>Change in Net Assets Before Non-Operating Activities</b>	(13,229,418)	(1,279,548)	(14,508,966)	(12,437,787)
<b>Non-Operating Activities</b>				
Loss on restructured pledge	(700,000)	--	(700,000)	--
Loss on disposal of fixed asset	(251,980)	--	(251,980)	--
Net investment income	336,081	--	336,081	3,161
<b>Change in Net Assets</b>	<u>(13,845,317)</u>	<u>(1,279,548)</u>	<u>(15,124,865)</u>	<u>(12,434,626)</u>
<b>Net Assets – Beginning of Year</b>	<u>34,756,401</u>	<u>12,650,925</u>	<u>47,407,326</u>	<u>59,841,952</u>
<b>Net Assets – End of Year</b>	<u>\$ 20,911,084</u>	<u>\$ 11,371,377</u>	<u>\$ 32,282,461</u>	<u>\$ 47,407,326</u>

*The accompanying notes are an integral part of these financial statements.*

**FOOD ALLERGY RESEARCH & EDUCATION, INC.**

**STATEMENT OF FUNCTIONAL EXPENSES**

**FOR THE YEAR ENDED DECEMBER 31, 2022**

**(WITH SUMMARIZED FINANCIAL INFORMATION FOR THE YEAR ENDED DECEMBER 31, 2021)**

	Program Services			Supporting Services			2022 Total	2021 Total	
	Research	Advocacy and Education	Shared Awareness and Outreach	Total Programs	Management and General	Fundraising			Total Supporting Services
Salaries	\$ 1,589,720	\$ 1,981,147	\$ 2,484,232	\$ 6,055,099	\$ 1,748,713	\$ 1,251,225	\$ 2,999,938	\$ 9,055,037	\$ 9,074,619
Other employee benefits	173,436	242,296	239,238	654,970	155,330	119,989	275,319	930,289	909,983
Payroll taxes	97,641	120,271	178,457	396,369	113,660	88,714	202,374	598,743	608,468
Retirement benefits	56,208	78,620	91,871	226,699	62,873	48,881	111,754	338,453	329,853
<b>Total personnel costs</b>	<b>1,917,005</b>	<b>2,422,334</b>	<b>2,993,798</b>	<b>7,333,137</b>	<b>2,080,576</b>	<b>1,508,809</b>	<b>3,589,385</b>	<b>10,922,522</b>	<b>10,922,923</b>
Research grants and sponsorships	8,884,604	210,276	6,000	9,100,880	2,800	--	2,800	9,103,680	7,162,852
Advertising and promotions	--	29,685	1,488,078	1,517,763	5,298	865	6,163	1,523,926	1,401,565
Conferences, events and travel	178,087	248,462	614,559	1,041,108	6,672	80,258	86,930	1,128,038	364,659
Other professional services	360,531	295,533	91,155	747,219	31,243	5,775	37,018	784,237	1,539,925
Clinical studies and patient registry	403,719	91,650	57,800	553,169	--	--	--	553,169	528,605
Depreciation, amortization and bad debt	--	--	--	--	75,872	410,000	485,872	485,872	77,109
Information technology	87,409	67,931	146,413	301,753	45,279	133,888	179,167	480,920	462,252
Office, insurance and other	42,216	63,870	80,632	186,718	34,559	109,193	143,752	330,470	312,971
Occupancy	50,864	94,627	78,960	224,451	43,037	56,187	99,224	323,675	273,593
Educational training and publications	--	200,456	110,637	311,093	--	--	--	311,093	432,706
Legal and audit fees	102,281	3,261	900	106,442	159,017	--	159,017	265,459	455,503
Medical honoraria	101,368	--	--	101,368	--	--	--	101,368	447,150
<b>Total Expenses</b>	<b>\$ 12,128,084</b>	<b>\$ 3,728,085</b>	<b>\$ 5,668,932</b>	<b>\$ 21,525,101</b>	<b>\$ 2,484,353</b>	<b>\$ 2,304,975</b>	<b>\$ 4,789,328</b>	<b>\$ 26,314,429</b>	<b>\$ 24,381,813</b>

*The accompanying notes are an integral part of these financial statements.*

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED DECEMBER 31, 2022

(WITH SUMMARIZED FINANCIAL INFORMATION FOR THE YEAR ENDED DECEMBER 31, 2021)

	2022	2021
<b>Cash Flows From Operating Activities</b>		
Change in net assets	\$ (15,124,865)	\$ (12,434,626)
Adjustments to reconcile change in net assets to net cash used in operating activities:		
Change in discount on contributions receivable	117,840	2,529
Provision for doubtful contributions receivable	85,000	5,000
Realized and unrealized gains on investments	(8,476)	(888)
Depreciation and amortization	75,872	72,110
Loss on disposal of fixed assets	251,980	--
Amortization of right-of-use assets	150,634	--
Change in discount on grants payable	--	(3,565)
Amortization of deferred lease benefit	--	(64,549)
Changes in assets and liabilities:		
Contributions receivable	369,700	1,921,659
Other receivables	(4,569)	42,009
Prepaid expenses and other assets	(110,994)	(120,322)
Accounts payable and accrued expenses	24,017	572,026
Accrued salaries, leave and other benefits	69,209	20,514
Grants payable	5,612,858	(211,560)
Refundable advances	50,000	--
Lease liability	(246,245)	--
Deferred rent	--	(22,351)
<b>Net Cash Used In Operating Activities</b>	<b>(8,688,039)</b>	<b>(10,222,014)</b>
<b>Cash Flows From Investing Activities</b>		
Purchases of property and equipment	(24,240)	(249,740)
Purchases of investments	(1,303,419)	(792)
Proceeds from the sale of investments	5,990,083	1,666,667
<b>Net Cash Provided By Investing Activities</b>	<b>4,662,424</b>	<b>1,416,135</b>
<b>Net Decrease In Cash and Cash Equivalents</b>	<b>(4,025,615)</b>	<b>(8,805,879)</b>
<b>Cash and Cash Equivalents – Beginning of Year</b>	<b>12,152,793</b>	<b>20,958,672</b>
<b>Cash and Cash Equivalents – End of Year</b>	<b>\$ 8,127,178</b>	<b>\$ 12,152,793</b>
<b>Cash and Cash Equivalents Reported on the Statement of Financial Position</b>		
Cash and cash equivalents	\$ 8,127,178	\$ 9,892,876
Cash and cash equivalents within investments	--	2,259,917
<b>Total Cash and Cash Equivalents</b>	<b>\$ 8,127,178</b>	<b>\$ 12,152,793</b>

*The accompanying notes are an integral part of these financial statements.*



# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

---

### NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### ***ORGANIZATION***

Food Allergy Research & Education, Inc. (FARE) is a 501(c)(3) public charity incorporated under the laws of New York. FARE is the nation's leading organization working on behalf of the 32 million Americans who have food allergies, including all those at risk for life-threatening anaphylaxis. FARE's mission is to improve the quality of life and the health of individuals with food allergies and to provide them hope through the promise of new treatments. FARE is a trusted source of information, programs and resources related to food allergy and anaphylaxis and the world's largest private source of funding for food allergy research. FARE's activities are funded primarily through grants and contributions.

#### ***CASH AND CASH EQUIVALENTS***

FARE considers all money market funds to be cash equivalents except that any such cash and cash equivalents held by external investment managers as part of FARE's designated investment portfolio are classified as investments.

#### ***INVESTMENTS***

Investments consist of a bond mutual fund and cash equivalents considered to be part of FARE's investment portfolio. These investments and cash equivalents are recorded in the accompanying financial statements at their fair value as of December 31<sup>st</sup>.

The change in unrealized appreciation or depreciation of investments is included in net investment income in the accompanying statement of activities. Realized gains and losses on sales of investments are computed on an average cost method and are recorded on the trade date of the transaction and included in net investment income in the accompanying statement of activities.

#### ***CONTRIBUTIONS AND OTHER RECEIVABLES***

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. FARE uses the allowance method to determine uncollectible receivables. The allowance is based on prior years' experience and management's analysis of specific contributions and other receivables. A provision for doubtful accounts is made when collection of the full amount is no longer probable.

#### ***PROPERTY AND EQUIPMENT AND RELATED DEPRECIATION AND AMORTIZATION***

Property and equipment are stated at cost and are depreciated on a straight-line basis over the estimated useful lives of the respective assets, which range from three to seven years. Leasehold improvements are amortized over the shorter of the lease period or useful life of the improvements. Expenditures for major repairs and improvements are capitalized; conversely, expenditures for minor repairs and maintenance costs are expensed when incurred.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2022

---

#### NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

##### *PROPERTY AND EQUIPMENT AND RELATED DEPRECIATION AND AMORTIZATION (CONTINUED)*

FARE's policy is to capitalize purchases of furniture, equipment and major repairs and improvements of \$5,000 or more. Software costs incurred during the development phase are capitalized as incurred and software purchases off-the-shelf are capitalized at cost and amortized over 5 years. On-going costs related to maintenance and training are expensed as incurred. Upon the retirement or disposal of assets, the cost and accumulated depreciation or amortization are eliminated from the respective accounts and the resulting gain or loss is included in non-operating activities.

##### *FAIR VALUE MEASUREMENT*

In accordance with accounting principles generally accepted in the United States of America (GAAP), applicable financial assets and liabilities are categorized based on inputs to valuation techniques as follows:

##### Level 1

Financial assets and liabilities whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market that FARE has the ability to access.

##### Level 2

Financial assets and liabilities whose values are based on quoted prices in markets that are not active or model inputs that are observable either directly or indirectly for substantially the full term of the asset or liability, such as quoted prices for similarly structured securities in active markets.

##### Level 3

Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the asset or liability.

As of and for the year ended December 31, 2022, only FARE's investments, as described in Note 4 of these financial statements, were measured at fair value on a recurring basis.

##### *CLASSIFICATION OF NET ASSETS*

Net assets without donor restrictions represent the portion of expendable funds that are available for support of FARE's operations or that have been designated by the Board for a particular purpose. Net assets with donor restrictions represent amounts that are specifically restricted by donors for various programs or future periods.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

---

### NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### *REVENUE RECOGNITION*

Contributions are reported as revenue in the year in which payments are received and/or unconditional promises are made. Conditional contributions – that is, those with a measurable performance or other barrier and a right of return, are not recognized until the conditions on which they depend have been met. FARE reports gifts of cash and other assets that are received with donor stipulations limiting the use of the donated assets as increases in net assets with donor restrictions. When a donor restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the accompanying statement of activities as net assets released from restrictions.

FARE considers its special events to be incidental to its operations and fundraising program. As such, FARE has elected to report its special event revenue net of direct special event costs in the accompanying statement of activities.

Program services fees consists of patient registry fees and educational courses. FARE recognizes the fees at the point in time in which the services are provided. Amounts earned but not received as of year-end are included in other receivables in the accompanying statement of financial position.

#### *FUNCTIONAL ALLOCATION OF EXPENSES*

The costs of providing the various programs and other activities have been summarized on a functional basis in the accompanying statement of functional expenses. Certain expenses have been directly applied to functions based upon the nature of the expense. Other expenses require allocation on a reasonable basis that is consistently applied. Salaries and benefits have been allocated on the basis of time and effort. Other indirect costs have been allocated based on the salaries and benefits allocation.

#### *ESTIMATES*

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates.

#### *MEASURE OF OPERATIONS*

FARE considers its net investment income, exclusive of the interest income earned on its cash and cash equivalents not considered part of its investment portfolio, gains and losses recognized on disposal of long term assets and losses on pledge restructuring, to be non-operating in nature.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

---

### NOTE 1 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

#### *NEW ACCOUNTING PRONOUNCEMENTS*

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the statement of financial position and disclosing key information about leasing arrangements for lessees and lessors. The standard applies a right of use model that requires, all leases with a lease term of more than 12 months, to recognize an asset representing its right to use the underlying asset for the lease term and liability to make lease payments to be recorded. FARE elected not to restate the comparative period. FARE also elected not to reassess at adoption (i) expired or existing contracts to determine whether they are or contain a lease, (ii) the lease classification of any existing leases, (iii) initial direct costs for existing leases. The adoption of ASU 2016-02 resulted in the recognition of operating right of use assets, net of lease incentives of \$123,728 and deferred rent of \$61,655, of \$339,764 and operating lease liabilities of \$525,147 as of January 1, 2022. Results for periods beginning prior to January 1, 2022 continue to be reported in accordance with FARE's historical accounting treatment. The adoption of ASU 2016-02 did not have a material impact on FARE's results of operations and cash flows.

### NOTE 2 - DESCRIPTION OF PROGRAMS AND SUPPORTING SERVICES

The following programs and supporting services of FARE are included in the accompanying financial statements:

#### Research

FARE is committed to supporting food allergy research progress in a number of ways. The cornerstone of these efforts was the launch of the FARE Clinical Network (FCN) in 2015. The FCN sites are changing the face of food allergy research by raising the quality of care for food allergic patients nationwide by reducing discrepancies in care among providers and by making comprehensive care available for all patients with food allergies. FCN sites are helping parents, caregivers and patients identify centers that provide clinical and sub-specialty food allergy services of the highest quality and that are leaders in rapidly applying new evidence-based knowledge.

Additionally, FCN centers are accelerating drug development for food allergy by enhancing infrastructure and capabilities to perform crucial late stage trials and providing the basis for a national food allergy patient registry and bio-repositories.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

---

### NOTE 2 - DESCRIPTION OF PROGRAMS AND SUPPORTING SERVICES (CONTINUED)

#### Research (continued)

FARE is driving innovation and advancing breakthroughs in food allergy diagnosis and treatment. FARE provides grants for foundational research that aim to transform the field of food allergy science leading to new therapies and cures. FARE has partnered with major medical centers at research universities to directly fund large scale, multi-million dollar and multi-year clinical studies and trials. These research studies are key steps in the approval of new therapies by the U.S. Food and Drug Administration (FDA). Major research study grants provided by FARE includes; oral immunotherapy (OIT) which introduces increasing amounts of an allergen, such as peanuts, to allergic individuals with the goal of increasing the threshold triggering a reaction; the FAITH challenge, a multi-million dollar competition designed to promote the development of food allergy diagnosis tools; the Gut-Brain study which maps the interplay of the brain, the gut and the immune system, which scientists expect will lead to therapies in food allergies.

#### Advocacy and Education

These activities cover a broad range of activities in support of FARE's mission including, but not limited to, national educational conferences, printed and online educational materials, the Community Outreach Awards program and Leaders Summit programs, free educational information disseminated through FARE's website and blogs, monthly webinar series on a variety of topics related to food allergy management, and FARE's college program efforts towards creating and training on best practices for identifying and serving the needs of students with food allergies in every aspect of student life. FARE's advocacy and education efforts include both digital and live campaigns, trainings, materials and other communication vehicles to educate and build awareness among relevant stakeholders of the severity of food allergies and appropriate policy accommodations. FARE also convenes food allergy experts, physicians, educators, policymakers, community leaders, patients, caregivers and advocates to support various mission efforts.

#### Shared Awareness and Outreach

These activities encompass a wide range of efforts including, but not limited to, executing national awareness campaigns to raise the profile of food allergy; distributing external communications including a bi-monthly e-newsletter and a quarterly research newsletter; maintenance and content writing for FARE's digital properties including its website and blogs, media outreach, marketing and promotion, monitoring services and other technology infrastructure support.

#### Management and General

Management and general includes the functions necessary to maintain an equitable employment program; ensure an adequate working environment; provide coordination and articulation of FARE's program strategy, and manage the financial and budgetary responsibilities of FARE.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

FOR THE YEAR ENDED DECEMBER 31, 2022

---

### NOTE 2 - DESCRIPTION OF PROGRAMS AND SUPPORTING SERVICES (CONTINUED)

#### Fundraising

Fundraising activities include FARE's efforts to solicit contributions from individuals, foundations, corporations and others.

### NOTE 3 - LIQUIDITY AND AVAILABILITY OF FINANCIAL RESOURCES

As of December 31, 2022, financial assets and liquidity resources available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statement of financial position date, were as follows:

Cash and cash equivalents	\$ 8,127,178
Investments	26,622,148
Contributions receivable, net, due within one year	2,738,910
Other receivables	<u>111,859</u>
Total financial assets available within one year	37,600,095
Less: Amounts unavailable for general expenditures within one year due to donor restrictions (purpose or time restrictions)	<u>(10,543,044)</u>
<b>Total Financial Assets Available to Meet General Expenditures Within One Year</b>	<b><u>\$ 27,057,051</u></b>

As outlined in Note 8 to these financial statements, FARE's Board of Directors has designated a portion of its resources totaling \$20,949,902 as of December 31, 2022 to be set aside as a reserve fund. However, these funds are liquid and remain available to be spent at the discretion of the Board and are therefore included in the total of financial assets available within one year above.

### NOTE 4 - INVESTMENTS AND FAIR VALUE

FARE has used the following fair value measurements as of December 31, 2022:

	<u>Total</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>
Bond mutual fund	<u>\$ 26,662,148</u>	<u>\$ 26,662,148</u>	<u>\$ --</u>	<u>\$ --</u>
<b>Total Investments</b>	<b><u>\$ 26,662,148</u></b>	<b><u>\$ 26,662,148</u></b>	<b><u>\$ --</u></b>	<b><u>\$ --</u></b>

The mutual fund held by FARE as of December 31, 2022 is listed on major securities exchanges with readily obtainable trading values and has been classified as "level 1" by FARE.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2022

---

#### NOTE 4 - INVESTMENTS AND FAIR VALUE (CONTINUED)

Investment returns for the year ended December 31, 2022 are summarized as follows:

Interest and dividends, net	\$ 344,557
Realized losses	<u>(8,476)</u>
<b>Net Investment Income</b>	<b><u>\$ 336,081</u></b>

#### NOTE 5 - CONTRIBUTIONS RECEIVABLE

As of December 31, 2022, contributions receivable consisted of the following:

Due in less than one year	\$ 2,838,910
Due in one to five years	<u>2,438,333</u>
Total	5,277,243
Less: Present value discount (4.42%)	(176,671)
Less: Allowance for doubtful accounts	<u>(100,000)</u>
<b>Contributions Receivable, Net</b>	<b><u>\$ 5,000,572</u></b>

FARE has received conditional grants which require certain milestones and/or the incurrence of other condition to be met prior to revenue recognition. During the year ended December 31, 2022, FARE recognized \$3,833,333 under these grants. As of December 31, 2022, FARE had not yet recognized \$500,000 under these awards as the qualifying milestones and/or conditions had not been met.

#### NOTE 6 - PROPERTY AND EQUIPMENT AND ACCUMULATED DEPRECIATION AND AMORTIZATION

FARE held the following property and equipment as of December 31, 2022:

Leasehold improvements	\$ 356,979
Office furniture and equipment	134,509
Software	<u>22,000</u>
Total	513,488
Less: Accumulated depreciation and amortization	<u>(430,372)</u>
<b>Property and Equipment, Net</b>	<b><u>\$ 83,116</u></b>

Depreciation expense totaled \$75,873 for the year ended December 31, 2022. Additionally, FARE incurred a loss on disposal of the mobile app totaling \$251,980

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2022

---

#### NOTE 7 - GRANTS PAYABLE

FARE awards grants for research to universities and hospital systems. As of December 31, 2022, all of FARE's unconditional promises to give were due within one year.

FARE has conditional promises to pay which require certain milestones and/or other conditions to meet prior to being paid. During the year ended December 31, 2022, FARE recognized \$6,550,000 in expenses under these grants. As of December 31, 2022, FARE had yet to recognize \$2,500,000 in expense as the milestones and/or other conditions had not yet been met.

#### NOTE 8 - NET ASSETS

##### Net Assets Without Donor Restrictions

The Board of Directors of FARE has designated a portion of net assets without donor restrictions as a reserve fund. The board designated net asset balance at December 31, 2022, was \$20,949,902 and there was a deficit in undesignated net assets totaling \$38,818.

##### Net Assets With Donor Restrictions

Net assets with donor restrictions are restricted to the following purposes or time periods as of December 31, 2022:

Research	\$ 4,595,480
Education	1,736,100
Research & Advocacy	2,773,131
General purposes for future years:	
Year ending December 31, 2023	828,333
Year ending December 31, 2024	693,333
Year ending December 31, 2025	405,000
Year ending December 31, 2026	<u>340,000</u>
<b>Total Net Assets With Donor Restrictions</b>	<b><u>\$ 11,371,377</u></b>

#### NOTE 9 - COMMITMENTS, RISKS AND CONTINGENCIES

##### Operating Leases

On January 1, 2022, FARE was required to adopt ASU 2016-02, Leases (Topic 842). The right-of-use (ROU) assets represent FARE's right to use underlying assets for the lease term, and the lease liabilities represent FARE's obligation to make lease payments arising from these leases.



# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2022

---

#### NOTE 9 - COMMITMENTS, RISKS AND CONTINGENCIES (CONTINUED)

##### Operating Leases (continued)

The ROU assets and lease liabilities, all of which arise from operating leases, were calculated based on the present value of future lease payments over the lease terms. If a lease agreement does not provide an implicit rate, based on the information available at the commencement date, the Association uses the risk-free rate. The Association's operating leases are described below.

In September 2017, FARE entered into an operating lease agreement for its current office space headquarters in McLean, VA. The lease commenced June 1, 2018 and expires November 30, 2023. The lease provides for a five-year renewal option; which management does not deem likely to exercise. The Virginia office lease contains fixed escalation clauses for increases in the annual minimum rent over the term of the lease. The Virginia office lease provided for rent abatement for the first six months of the lease term. Additionally, the Virginia office lease included an allowance of approximately \$355,000 as an incentive to enter into the lease.

Additionally, FARE also has leases for storage space, and two copiers with lease terms expiring between November 2024 and November 2025.

Aggregate future lease payments below summarize the remaining future undiscounted cash flows for operating leases as of December 31, 2022 and a reconciliation to operating lease liabilities reported on the statement of financial position:

For the Year Ending <u>December 31,</u>	
2023	\$ 251,704
2024	15,692
2025	<u>5,993</u>
Total Lease Payments	273,389
Less Interest	<u>(2,437)</u>
<b>Present Value of Lease Liability</b>	<b><u>\$ 270,952</u></b>

Operating lease expense under the leases was \$159,381 and variable lease expenses incurred totaled \$164,294 for the year end December 31, 2022 which are included in occupancy on the statement of functional expenses. Cash payments for operating leases during the year ended December 31, 2022 totaled \$254,992.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2022

---

#### NOTE 9 - COMMITMENTS, RISKS AND CONTINGENCIES (CONTINUED)

##### Operating Leases (continued)

Average operating lease terms and discount rate as of December 31, 2022 were as follows:

Weighted Average Remaining Lease Terms (Years)	1.13
Weighted Average Discount Rate	1.50%

##### Concentration of Credit Risk

FARE's cash is comprised of amounts in accounts at various financial institutions. While the amount at times exceeds the amount guaranteed by federal agencies and, therefore, bears some risk, FARE has not experienced, nor does it anticipate, any loss of funds. As of December 31, 2022, the Federal Deposit Insurance Corporation (FDIC) insured balances of a depositor, per financial institution, up to \$250,000. The amount held by FARE in excess of the FDIC insured limit was approximately \$32,937,000 as of December 31, 2022.

#### NOTE 10 - RETIREMENT SAVINGS PLAN

Effective January 1, 1998, FARE adopted a defined contribution plan under Section 401(k) of the Internal Revenue Code. Employees are eligible to participate in the plan immediately upon their hire and may elect to contribute up to the Federal tax limitations. Employer contributions under the plan are equal to 4% of an eligible participant's compensation. Additional employer discretionary contributions are permitted.

Employees are immediately vested in the full value of their accounts, including employer contributions. The plan includes a provision allowing loans from the plan.

Retirement plan expense for the year ended December 31, 2022, was \$338,454 and is included in retirement benefits in the accompanying statement of functional expenses.

#### NOTE 11 - JOINT COSTS

During the year ended December 31, 2022, FARE incurred joint costs of approximately \$904,560 from activities including events and digital and print communications that included both educational and fundraising appeals. Of those costs, approximately \$123,916 was allocated to fundraising, \$173,674 was allocated to management and general, \$245,875 was allocated to the Shared Awareness and Outreach program, \$198,942 was allocated to the Advocacy and Education program and \$162,153 was allocated to the Research program.

# FOOD ALLERGY RESEARCH & EDUCATION, INC.

## NOTES TO FINANCIAL STATEMENTS

### FOR THE YEAR ENDED DECEMBER 31, 2022

---

#### NOTE 12 - INCOME TAXES

FARE is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is exempt from federal taxes on income other than net unrelated business income. There was no provision for income tax for FARE for the year ended December 31, 2022 as FARE had no unrelated business income.

FARE reviews and assesses all activities annually to identify any changes in the scope of the activities and revenue sources and the tax treatment thereof to identify any uncertainty in income tax. For the year ended December 31, 2022, management did not identify any uncertainty in income tax requiring recognition or disclosure in these financial statements.

FARE's tax returns are subject to possible examination by the taxing authorities. For federal tax purposes, the tax returns remain open for possible examination for a period of three years after the respective filing deadlines of those returns.

#### NOTE 13 - RECLASSIFICATIONS

Certain 2021 amounts have been reclassified to conform with the 2022 financial statement presentations.

#### NOTE 14 - PRIOR YEAR SUMMARIZED FINANCIAL INFORMATION

The accompanying financial statements include certain prior year summarized comparative information in total, but not by net asset class. Accordingly, such information should be read in conjunction with FARE's financial statements for the year ended December 31, 2021, from which the summarized information was derived.

#### NOTE 15 - SUBSEQUENT EVENTS

FARE's management has evaluated subsequent events through September 14, 2023, the date the financial statements were available to be issued. Except as disclosed below, there were no subsequent events identified through September 14, 2023, required to be disclosed in these financial statements.

In July 2023, FARE renegotiated its Maclean, VA lease to extend the lease term for one additional year, set to expire in November 2024.